Initiation of dosing in our Phase 1b clinical trial represents an important step in the clinical development of GT-02287 and in Gain’s mission to deliver a disease-modifying therapy to people with ...

Interim Analysis Expected End of 2Q 2025 BETHESDA, MD / ACCESS Newswire / March 14, 2025 / Gain Therapeutics, Inc. (Nasdaq:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company lead ...

Gain Therapeutics (GANX) announced the dosing of the first participant with Parkinson’s disease in its Phase 1b clinical trial of GT-02287, the ...